Mersana Therapeutics, Inc. (MRSN) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRSN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MRSN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MRSN P/E vs Peers
Cancer Antibodies & ADCs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $298M | 21.2 | - | +100% | |
| $9B | 21.3 | - | +1747%Best | |
| $420M | 18.4Lowest | - | -2% | |
| $168B | 41.9 | - | -4% | |
| $362B | 148.2 | 6.98Best | +8% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MRSN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MRSN — Frequently Asked Questions
Quick answers to the most common questions about buying MRSN stock.
What is MRSN's P/E ratio?
Mersana Therapeutics, Inc. (MRSN) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is MRSN stock overvalued or undervalued?
MRSN current P/E: N/A. 5-year average P/E: N/A. Percentile: N/A.
Is MRSN stock expensive?
MRSN is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of N/A (N/A percentile of historical range).
What is MRSN's historical P/E range?
Over the past 5 years, MRSN's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does MRSN's P/E compare to the S&P 500?
MRSN current P/E: N/A. S&P 500 median P/E: 21.8x.
How does MRSN's valuation compare to Healthcare peers?
Mersana Therapeutics, Inc. P/E of N/A can be benchmarked against Healthcare peers in the comparison table on this page.
What is MRSN's PEG ratio?
MRSN PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MRSN's earnings yield?
MRSN earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.